{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T05:02:13Z","timestamp":1785733333839,"version":"3.56.0"},"reference-count":147,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejinme.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.ejim.2023.06.008","type":"journal-article","created":{"date-parts":[[2023,6,17]],"date-time":"2023-06-17T09:02:52Z","timestamp":1686992572000},"page":"18-28","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Future treatments in hypertension: Can we meet the unmet needs of patients?"],"prefix":"10.1016","volume":"115","author":[{"given":"Mehmet","family":"Kanbay","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sidar","family":"Copur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cem","family":"Tanriover","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duygu","family":"Ucku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke","family":"Laffin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.ejim.2023.06.008_bib0001","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/jhh.2013.140","article-title":"Apparent and true resistant hypertension: definition, prevalence and outcomes","volume":"28","author":"Judd","year":"2014","journal-title":"J Hum Hypertens"},{"issue":"4","key":"10.1016\/j.ejim.2023.06.008_bib0002","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1097\/HCO.0000000000000642","article-title":"Status of hypertension in Europe","volume":"34","author":"Reuter","year":"2019","journal-title":"Curr Opin Cardiol"},{"issue":"7","key":"10.1016\/j.ejim.2023.06.008_bib0003","doi-asserted-by":"crossref","first-page":"e736","DOI":"10.1016\/S2214-109X(18)30259-6","article-title":"May measurement month 2017: an analysis of blood pressure screening results worldwide","volume":"6","author":"Beaney","year":"2018","journal-title":"Lancet Glob Health"},{"issue":"6","key":"10.1016\/j.ejim.2023.06.008_bib0004","first-page":"e13","volume":"71","author":"Whelton","year":"2018","journal-title":"Hypertension"},{"issue":"6","key":"10.1016\/j.ejim.2023.06.008_bib0005","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1161\/HYPERTENSIONAHA.120.15026","article-title":"2020 international society of hypertension global hypertension practice guidelines","volume":"75","author":"Unger","year":"2020","journal-title":"Hypertension."},{"issue":"10","key":"10.1016\/j.ejim.2023.06.008_bib0006","doi-asserted-by":"crossref","first-page":"e146","DOI":"10.1161\/CIR.0000000000000485","article-title":"Heart disease and stroke statistics\u20142017 update: a report from the American heart association","volume":"135","author":"Benjamin","year":"2017","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.ejim.2023.06.008_bib0007","doi-asserted-by":"crossref","first-page":"173","DOI":"10.17219\/acem\/58998","article-title":"Resistant hypertension","volume":"25","author":"Doroszko","year":"2016","journal-title":"Adv Clin Exp Med"},{"issue":"4","key":"10.1016\/j.ejim.2023.06.008_bib0008","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.cpcardiol.2007.01.002","article-title":"Systemic hypertension","volume":"32","author":"Elliott","year":"2007","journal-title":"Curr Probl Cardiol"},{"key":"10.1016\/j.ejim.2023.06.008_bib0009","doi-asserted-by":"crossref","DOI":"10.1093\/ckj\/sfad059","article-title":"A new immune disease: systemic hypertension","author":"Copur","year":"2023","journal-title":"Clin Kidney J"},{"issue":"4","key":"10.1016\/j.ejim.2023.06.008_bib0010","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/s41581-019-0244-2","article-title":"The global epidemiology of hypertension","volume":"16","author":"Mills","year":"2020","journal-title":"Nat Rev Nephrol"},{"issue":"5","key":"10.1016\/j.ejim.2023.06.008_bib0011","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1161\/HYPERTENSIONAHA.110.168948","article-title":"Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring","volume":"57","author":"de la","year":"2011","journal-title":"Hypertension"},{"issue":"6","key":"10.1016\/j.ejim.2023.06.008_bib0012","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1161\/HYPERTENSIONAHA.111.170308","article-title":"Prevalence of resistant hypertension in the United States, 2003-2008","volume":"57","author":"Persell","year":"2011","journal-title":"Hypertension"},{"issue":"6","key":"10.1016\/j.ejim.2023.06.008_bib0013","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1161\/HYPERTENSIONAHA.108.189141","article-title":"Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American heart association professional education committee of the council for high blood pressure research","volume":"51","author":"Calhoun","year":"2008","journal-title":"Hypertension"},{"issue":"7","key":"10.1016\/j.ejim.2023.06.008_bib0014","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1097\/01.hjh.0000431740.32696.cc","article-title":"2013 ESH\/ESC guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European society of hypertension (ESH) and of the European society of cardiology (ESC)","volume":"31","author":"Mancia","year":"2013","journal-title":"J Hypertens"},{"issue":"6","key":"10.1016\/j.ejim.2023.06.008_bib0015","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1007\/s11906-008-0092-0","article-title":"Resistant hypertension and hyperaldosteronism","volume":"10","author":"Gonzaga","year":"2008","journal-title":"Curr Hypertens Rep"},{"issue":"22","key":"10.1016\/j.ejim.2023.06.008_bib0016","doi-asserted-by":"crossref","first-page":"E773","DOI":"10.1503\/cmaj.161486","article-title":"Primary aldosteronism: a common cause of resistant hypertension","volume":"189","author":"Kline","year":"2017","journal-title":"CMAJ"},{"issue":"3","key":"10.1016\/j.ejim.2023.06.008_bib0017","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1161\/HYPERTENSIONAHA.119.14359","article-title":"Screening rates for primary aldosteronism in resistant hypertension","volume":"75","author":"Jaffe","year":"2020","journal-title":"Hypertension"},{"issue":"9628","key":"10.1016\/j.ejim.2023.06.008_bib0018","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1016\/S0140-6736(08)60834-X","article-title":"Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational study","volume":"371","author":"Douma","year":"2008","journal-title":"Lancet"},{"issue":"Suppl_1","key":"10.1016\/j.ejim.2023.06.008_bib0019","doi-asserted-by":"crossref","DOI":"10.1161\/hyp.76.suppl_1.P233","article-title":"Abstract P233: inhibition of aldosterone synthesis in non-human primates by PB6440, the novel highly selective and potent CYP11B2 inhibitor","volume":"76","author":"Pitt","year":"2020","journal-title":"Hypertension"},{"key":"10.1016\/j.ejim.2023.06.008_bib0020","article-title":"Phase 2 trial of baxdrostat for treatment-resistant hypertension","author":"Freeman","year":"2022","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ejim.2023.06.008_bib0021","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1161\/HYPERTENSIONAHA.116.07716","article-title":"Preclinical and early clinical profile of a highly selective and potent oral inhibitor of aldosterone synthase (CYP11B2)","volume":"69","author":"Bogman","year":"2017","journal-title":"Hypertension"},{"issue":"1","key":"10.1016\/j.ejim.2023.06.008_bib0022","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/s41440-022-01070-4","article-title":"Results from a phase 1, randomized, double-blind, multiple ascending dose study characterizing the pharmacokinetics and demonstrating the safety and selectivity of the aldosterone synthase inhibitor baxdrostat in healthy volunteers","volume":"46","author":"Freeman","year":"2023","journal-title":"Hypertens Res"},{"key":"10.1016\/j.ejim.2023.06.008_bib0023","doi-asserted-by":"crossref","DOI":"10.1007\/s11102-022-01268-2","article-title":"Treatment of cushing's syndrome with osilodrostat: practical applications of recent studies with case examples","author":"Fleseriu","year":"2022","journal-title":"Pituitary"},{"key":"10.1016\/j.ejim.2023.06.008_bib0024","unstructured":"2023 [Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/212801s000lbl.pdf. Accessed 15 June 2023."},{"issue":"7","key":"10.1016\/j.ejim.2023.06.008_bib0025","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/BF03349766","article-title":"11 Beta-hydroxylase deficiency","volume":"18","author":"Mantero","year":"1995","journal-title":"J Endocrinol Invest"},{"issue":"9","key":"10.1016\/j.ejim.2023.06.008_bib0026","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/S2213-8587(20)30240-0","article-title":"Efficacy and safety of osilodrostat in patients with Cushing's disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase","volume":"8","author":"Pivonello","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"18","key":"10.1016\/j.ejim.2023.06.008_bib0027","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1161\/CIRCULATIONAHA.111.029892","article-title":"Effects of a novel aldosterone synthase inhibitor for treatment of primary hypertension: results of a randomized, double-blind, placebo- and active-controlled phase 2 trial","volume":"124","author":"Calhoun","year":"2011","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.ejim.2023.06.008_bib0028","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/jch.12051","article-title":"Study of aldosterone synthase inhibition as an add-on therapy in resistant hypertension","volume":"15","author":"Karns","year":"2013","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"9","key":"10.1016\/j.ejim.2023.06.008_bib0029","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1111\/j.1751-7176.2012.00667.x","article-title":"The effects of aldosterone synthase inhibition on aldosterone and cortisol in patients with hypertension: a phase II, randomized, double-blind, placebo-controlled, multicenter study","volume":"14","author":"Andersen","year":"2012","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"2","key":"10.1016\/j.ejim.2023.06.008_bib0030","first-page":"296","article-title":"Efficacy and safety of LCI699 for hypertension: a meta-analysis of randomized controlled trials and systematic review","volume":"19","author":"Wang","year":"2015","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"3","key":"10.1016\/j.ejim.2023.06.008_bib0031","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s11906-020-1023-y","article-title":"Mineralocorticoid receptor blockers: novel selective nonsteroidal mineralocorticoid receptor antagonists","volume":"22","author":"Sueta","year":"2020","journal-title":"Curr Hypertens Rep"},{"issue":"1","key":"10.1016\/j.ejim.2023.06.008_bib0032","doi-asserted-by":"crossref","first-page":"T125","DOI":"10.1530\/JOE-16-0600","article-title":"30 years of the mineralocorticoid receptor: Mineralocorticoid receptor antagonists: 60 years of research and development","volume":"234","author":"Kolkhof","year":"2017","journal-title":"J Endocrinol"},{"issue":"3","key":"10.1016\/j.ejim.2023.06.008_bib0033","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1161\/HYPERTENSIONAHA.107.103580","article-title":"A number of marketed dihydropyridine calcium channel blockers have mineralocorticoid receptor antagonist activity","volume":"51","author":"Dietz","year":"2008","journal-title":"Hypertension"},{"key":"10.1016\/j.ejim.2023.06.008_bib0034","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.ejphar.2015.06.015","article-title":"Pharmacological profile of CS-3150, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist","volume":"761","author":"Arai","year":"2015","journal-title":"Eur J Pharmacol"},{"issue":"12","key":"10.1016\/j.ejim.2023.06.008_bib0035","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1080\/00498254.2016.1263766","article-title":"Pharmacokinetics, distribution, and disposition of esaxerenone, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist, in rats and monkeys","volume":"47","author":"Yamada","year":"2017","journal-title":"Xenobiotica"},{"issue":"8","key":"10.1016\/j.ejim.2023.06.008_bib0036","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1111\/bcp.13616","article-title":"Single- and multiple-dose escalation study to assess pharmacokinetics, pharmacodynamics and safety of oral esaxerenone in healthy Japanese subjects","volume":"84","author":"Kato","year":"2018","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.ejim.2023.06.008_bib0037","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1124\/dmd.118.084897","article-title":"Pharmacokinetics, metabolism, and excretion of [(14)C]esaxerenone, a novel mineralocorticoid receptor Blocker in humans","volume":"47","author":"Yamada","year":"2019","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"10.1016\/j.ejim.2023.06.008_bib0038","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1161\/HYPERTENSIONAHA.119.13569","article-title":"Double-blind randomized phase 3 study comparing esaxerenone (CS-3150) and eplerenone in patients with essential hypertension (ESAX-HTN study)","volume":"75","author":"Ito","year":"2020","journal-title":"Hypertension."},{"issue":"10","key":"10.1016\/j.ejim.2023.06.008_bib0039","doi-asserted-by":"crossref","first-page":"4779","DOI":"10.1007\/s12325-022-02282-3","article-title":"Antihypertensive effect of long-term monotherapy with esaxerenone in patients with essential hypertension: relationship between baseline urinary sodium excretion and its antihypertensive effect","volume":"39","author":"Ichikawa","year":"2022","journal-title":"Adv Ther"},{"issue":"10","key":"10.1016\/j.ejim.2023.06.008_bib0040","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1007\/s11886-022-01750-0","article-title":"Effects of finerenone, a novel nonsteroidal mineralocorticoid receptor antagonist, on cardiovascular disease, chronic kidney disease, and blood pressure","volume":"24","author":"Ravid","year":"2022","journal-title":"Curr Cardiol Rep"},{"issue":"12","key":"10.1016\/j.ejim.2023.06.008_bib0041","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1161\/HYPERTENSIONAHA.122.19744","article-title":"Blood pressure and cardiorenal outcomes with finerenone in chronic kidney disease in type 2 diabetes","volume":"79","author":"Ruilope","year":"2022","journal-title":"Hypertension"},{"issue":"1","key":"10.1016\/j.ejim.2023.06.008_bib0042","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/ejhf.444","article-title":"Non-steroidal mineralocorticoid receptor antagonism for the treatment of cardiovascular and renal disease","volume":"18","author":"Bramlage","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ejim.2023.06.008_bib0043","doi-asserted-by":"crossref","DOI":"10.1016\/j.mce.2021.111254","article-title":"Renin-angiotensin system and inflammation update","volume":"529","author":"Cantero-Navarro","year":"2021","journal-title":"Mol Cell Endocrinol"},{"issue":"4","key":"10.1016\/j.ejim.2023.06.008_bib0044","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S1043-2760(01)00381-2","article-title":"Angiotensin III: a central regulator of vasopressin release and blood pressure","volume":"12","author":"Reaux","year":"2001","journal-title":"Trends Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.ejim.2023.06.008_bib0045","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s40262-013-0125-y","article-title":"Randomised, double-blind, placebo-controlled, dose-escalating phase I study of QGC001, a centrally acting aminopeptidase a inhibitor prodrug","volume":"53","author":"Balavoine","year":"2014","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"10.1016\/j.ejim.2023.06.008_bib0046","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4103\/ajm.ajm_117_20","article-title":"Abu-Zaid A. Firibastat, the first-in-class brain aminopeptidase a inhibitor, in the management of hypertension: A review of clinical trials","volume":"11","author":"Alomar","year":"2021","journal-title":"Avicenna J Med"},{"issue":"8","key":"10.1016\/j.ejim.2023.06.008_bib0047","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1097\/HJH.0000000000002092","article-title":"A pilot double-blind randomized placebo-controlled crossover pharmacodynamic study of the centrally active aminopeptidase A inhibitor, firibastat, in hypertension","volume":"37","author":"Azizi","year":"2019","journal-title":"J Hypertens"},{"issue":"2","key":"10.1016\/j.ejim.2023.06.008_bib0048","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1161\/CIRCULATIONAHA.119.040070","article-title":"Efficacy and safety of Firibastat, a first-in-class brain aminopeptidase A inhibitor, in hypertensive overweight patients of multiple ethnic origins: A Phase 2, open-label, multicenter, dose-titrating study","volume":"140","author":"Ferdinand","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2023.06.008_bib0049","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.111682","article-title":"Llorens-Cortes C. Effects of firibastat in combination with enalapril and hydrochlorothiazide on blood pressure and vasopressin release in hypertensive DOCA-salt rats","volume":"140","author":"Marc","year":"2021","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"10.1016\/j.ejim.2023.06.008_bib0050","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1159\/000504623","article-title":"The role of endothelin and endothelin antagonists in chronic kidney disease","volume":"6","author":"Raina","year":"2020","journal-title":"Kidney Dis"},{"key":"10.1016\/j.ejim.2023.06.008_bib0051","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1146\/annurev.pharmtox.47.120505.105134","article-title":"Contrasting actions of endothelin ET(A) and ET(B) receptors in cardiovascular disease","volume":"47","author":"Schneider","year":"2007","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"12","key":"10.1016\/j.ejim.2023.06.008_bib0052","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1056\/NEJM199803193381202","article-title":"The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. Bosentan Hypertension Investigators","volume":"338","author":"Krum","year":"1998","journal-title":"N Engl J Med"},{"issue":"7 Pt 1","key":"10.1016\/j.ejim.2023.06.008_bib0053","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S0895-7061(02)02933-3","article-title":"Darusentan: an effective endothelinA receptor antagonist for treatment of hypertension","volume":"15","author":"Nakov","year":"2002","journal-title":"Am J Hypertens"},{"issue":"9699","key":"10.1016\/j.ejim.2023.06.008_bib0054","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S0140-6736(09)61500-2","article-title":"A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial","volume":"374","author":"Weber","year":"2009","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.ejim.2023.06.008_bib0055","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1161\/HYPERTENSIONAHA.110.156976","article-title":"Divergent results using clinic and ambulatory blood pressures","volume":"56","author":"Bakris","year":"2010","journal-title":"Hypertension"},{"key":"10.1016\/j.ejim.2023.06.008_bib0056","doi-asserted-by":"crossref","first-page":"949","DOI":"10.2147\/DDDT.S199051","article-title":"Single- and multiple-dose tolerability, safety, pharmacokinetics, and pharmacodynamics of the dual endothelin receptor antagonist aprocitentan in healthy adult and elderly subjects","volume":"13","author":"Sidharta","year":"2019","journal-title":"Drug Des Devel Ther"},{"issue":"5","key":"10.1016\/j.ejim.2023.06.008_bib0057","doi-asserted-by":"crossref","first-page":"399","DOI":"10.2174\/1389200222666210204202815","article-title":"Absorption, distribution, metabolism, and excretion of aprocitentan, a dual endothelin receptor antagonist, in humans","volume":"22","author":"Sidharta","year":"2021","journal-title":"Curr Drug Metab"},{"issue":"2","key":"10.1016\/j.ejim.2023.06.008_bib0058","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s40119-021-00233-7","article-title":"A dual endothelin receptor antagonist under development for the treatment of resistant hypertension","volume":"10","author":"Angeli","year":"2021","journal-title":"Cardiol Ther"},{"issue":"4","key":"10.1016\/j.ejim.2023.06.008_bib0059","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1161\/HYPERTENSIONAHA.119.14504","article-title":"Randomized dose-response study of the new dual endothelin receptor antagonist aprocitentan in hypertension","volume":"75","author":"Verweij","year":"2020","journal-title":"Hypertension"},{"issue":"10367","key":"10.1016\/j.ejim.2023.06.008_bib0060","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1016\/S0140-6736(22)02034-7","article-title":"Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial","volume":"400","author":"Schlaich","year":"2022","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.ejim.2023.06.008_bib0061","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/sj.clpt.6100214","article-title":"Polymorphisms of ACE2 gene are associated with essential hypertension and antihypertensive effects of Captopril in women","volume":"82","author":"Fan","year":"2007","journal-title":"Clin Pharmacol Ther"},{"issue":"7","key":"10.1016\/j.ejim.2023.06.008_bib0062","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/nrcardio.2014.59","article-title":"Angiotensin-converting enzyme 2 and angiotensin 1-7: novel therapeutic targets","volume":"11","author":"Jiang","year":"2014","journal-title":"Nat Rev Cardiol"},{"issue":"14","key":"10.1016\/j.ejim.2023.06.008_bib0063","doi-asserted-by":"crossref","first-page":"8258","DOI":"10.1073\/pnas.1432869100","article-title":"Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas","volume":"100","author":"Santos","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"10.1016\/j.ejim.2023.06.008_bib0064","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1097\/MNH.0000000000000254","article-title":"Angiotensin converting enzyme 2 and diminazene: role in cardiovascular and blood pressure regulation","volume":"25","author":"Velkoska","year":"2016","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"1","key":"10.1016\/j.ejim.2023.06.008_bib0065","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s11906-012-0324-1","article-title":"Opportunities for targeting the angiotensin-converting enzyme 2\/angiotensin-(1-7)\/mas receptor pathway in hypertension","volume":"15","author":"Fraga-Silva","year":"2013","journal-title":"Curr Hypertens Rep"},{"issue":"4","key":"10.1016\/j.ejim.2023.06.008_bib0066","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1097\/HJH.0000000000000094","article-title":"Angiotensin-(1-9) reverses experimental hypertension and cardiovascular damage by inhibition of the angiotensin converting enzyme\/Ang II axis","volume":"32","author":"Ocaranza","year":"2014","journal-title":"J Hypertens"},{"issue":"6","key":"10.1016\/j.ejim.2023.06.008_bib0067","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1161\/CIRCRESAHA.116.303603","article-title":"New approaches in the treatment of hypertension","volume":"116","author":"Oparil","year":"2015","journal-title":"Circ Res"},{"issue":"6","key":"10.1016\/j.ejim.2023.06.008_bib0068","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1161\/CIRCRESAHA.116.303587","article-title":"Hypertension: renin-angiotensin-aldosterone system alterations","volume":"116","author":"Te Riet","year":"2015","journal-title":"Circ Res"},{"issue":"9","key":"10.1016\/j.ejim.2023.06.008_bib0069","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1007\/s40262-013-0072-7","article-title":"Pharmacokinetics and pharmacodynamics of recombinant human angiotensin-converting enzyme 2 in healthy human subjects","volume":"52","author":"Haschke","year":"2013","journal-title":"Clin Pharmacokinet"},{"issue":"227","key":"10.1016\/j.ejim.2023.06.008_bib0070","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3007790","article-title":"Intestinal inhibition of the Na+\/H+ exchanger 3 prevents cardiorenal damage in rats and inhibits Na+ uptake in humans","volume":"6","author":"Spencer","year":"2014","journal-title":"Sci Transl Med"},{"issue":"1","key":"10.1016\/j.ejim.2023.06.008_bib0071","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1161\/HYPERTENSIONAHA.116.08484","article-title":"Effects of sacubitril\/valsartan (LCZ696) on natriuresis, diuresis, blood pressures, and NT-proBNP in salt-sensitive hypertension","volume":"69","author":"Wang","year":"2017","journal-title":"Hypertension"},{"issue":"36","key":"10.1016\/j.ejim.2023.06.008_bib0072","doi-asserted-by":"crossref","first-page":"3741","DOI":"10.1093\/eurheartj\/ehab499","article-title":"Sacubitril-valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction","volume":"42","author":"Jackson","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2023.06.008_bib0073","article-title":"Network meta-analysis of sacubitril\/valsartan for the treatment of essential hypertension","author":"Zhang","year":"2022","journal-title":"Clin Res Cardiol"},{"issue":"3","key":"10.1016\/j.ejim.2023.06.008_bib0074","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1021\/jm051051f","article-title":"Synthesis and biological evaluation of novel, peripherally selective chromanyl imidazolethione-based inhibitors of dopamine beta-hydroxylase","volume":"49","author":"Beliaev","year":"2006","journal-title":"J Med Chem"},{"issue":"12","key":"10.1016\/j.ejim.2023.06.008_bib0075","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1016\/j.clinthera.2013.10.012","article-title":"Etamicastat, a novel dopamine \u03b2-hydroxylase inhibitor: tolerability, pharmacokinetics, and pharmacodynamics in patients with hypertension","volume":"35","author":"Almeida","year":"2013","journal-title":"Clin Ther"},{"issue":"1","key":"10.1016\/j.ejim.2023.06.008_bib0076","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/hr.2014.143","article-title":"Blood pressure-decreasing effect of etamicastat alone and in combination with antihypertensive drugs in the spontaneously hypertensive rat","volume":"38","author":"Igreja","year":"2015","journal-title":"Hypertens Res"},{"key":"10.1016\/j.ejim.2023.06.008_bib0077","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1146\/annurev.pharmtox.45.120403.095920","article-title":"Epoxide hydrolases: mechanisms, inhibitor designs, and biological roles","volume":"45","author":"Morisseau","year":"2005","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"11","key":"10.1016\/j.ejim.2023.06.008_bib0078","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1042\/CS20110622","article-title":"Inhibition of soluble epoxide hydrolase by cis-4-[4-(3-adamantan-1-ylureido)cyclohexyl-oxy]benzoic acid exhibits antihypertensive and cardioprotective actions in transgenic rats with angiotensin II-dependent hypertension","volume":"122","author":"Neck\u00e1\u0159","year":"2012","journal-title":"Clin Sci (Lond)"},{"issue":"49","key":"10.1016\/j.ejim.2023.06.008_bib0079","doi-asserted-by":"crossref","first-page":"18733","DOI":"10.1073\/pnas.0609158103","article-title":"Prevention and reversal of cardiac hypertrophy by soluble epoxide hydrolase inhibitors","volume":"103","author":"Xu","year":"2006","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"3","key":"10.1016\/j.ejim.2023.06.008_bib0080","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/j.bmcl.2010.12.042","article-title":"1-(1-acetyl-piperidin-4-yl)-3-adamantan-1-yl-urea (AR9281) as a potent, selective, and orally available soluble epoxide hydrolase inhibitor with efficacy in rodent models of hypertension and dysglycemia","volume":"21","author":"Anandan","year":"2011","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.ejim.2023.06.008_bib0081","series-title":"A novel inhibitor of soluble epoxide hydrolase, AR9281, improves glucose homeostasis in diet-induced obese mice. Diabetes","author":"Wong","year":"2009"},{"issue":"3","key":"10.1016\/j.ejim.2023.06.008_bib0082","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1177\/0091270010397049","article-title":"Pharmacokinetics and pharmacodynamics of AR9281, an inhibitor of soluble epoxide hydrolase, in single- and multiple-dose studies in healthy human subjects","volume":"52","author":"Chen","year":"2012","journal-title":"J Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.ejim.2023.06.008_bib0083","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/0002-8703(89)90767-9","article-title":"Immunologic approaches to blockade of the renin-angiotensin system: a review","volume":"117","author":"Michel","year":"1989","journal-title":"Am Heart J"},{"issue":"1","key":"10.1016\/j.ejim.2023.06.008_bib0084","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.ijcard.2009.10.027","article-title":"A vaccine for hypertension based on peptide AngI-R: a pilot study","volume":"148","author":"Hong","year":"2011","journal-title":"Int J Cardiol"},{"issue":"5","key":"10.1016\/j.ejim.2023.06.008_bib0085","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1046\/j.1365-2125.2003.01926.x","article-title":"Evaluation of two carrier protein-angiotensin I conjugate vaccines to assess their future potential to control high blood pressure (hypertension) in man","volume":"56","author":"Downham","year":"2003","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.ejim.2023.06.008_bib0086","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1042\/CS20030381","article-title":"Randomized double-blind placebo-controlled study of an angiotensin immunotherapeutic vaccine (PMD3117) in hypertensive subjects","volume":"107","author":"Brown","year":"2004","journal-title":"Clin Sci"},{"issue":"1","key":"10.1016\/j.ejim.2023.06.008_bib0087","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/HJH.0b013e32800ff5d6","article-title":"A vaccine for hypertension based on virus-like particles: preclinical efficacy and phase I safety and immunogenicity","volume":"25","author":"Amb\u00fchl","year":"2007","journal-title":"J Hypertens"},{"issue":"9615","key":"10.1016\/j.ejim.2023.06.008_bib0088","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/S0140-6736(08)60381-5","article-title":"Effect of immunisation against angiotensin II with CYT006-AngQb on ambulatory blood pressure: a double-blind, randomised, placebo-controlled phase IIa study","volume":"371","author":"Tissot","year":"2008","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.ejim.2023.06.008_bib0089","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/nrcardio.2009.156","article-title":"Success and failure of vaccines against renin-angiotensin system components","volume":"6","author":"Brown","year":"2009","journal-title":"Nat Rev Cardiol"},{"issue":"6","key":"10.1016\/j.ejim.2023.06.008_bib0090","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1161\/CIRCRESAHA.116.303603","article-title":"New approaches in the treatment of hypertension","volume":"116","author":"Oparil","year":"2015","journal-title":"Circ Res"},{"issue":"1","key":"10.1016\/j.ejim.2023.06.008_bib0091","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1161\/01.HYP.0000196685.91424.01","article-title":"Potential of gene therapy strategy for the treatment of hypertension","volume":"47","author":"Raizada","year":"2006","journal-title":"Hypertension"},{"issue":"4","key":"10.1016\/j.ejim.2023.06.008_bib0092","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1161\/HYPERTENSIONAHA.120.16471","article-title":"Polygenic risk scores predict hypertension onset and cardiovascular risk","volume":"77","author":"Vaura","year":"2021","journal-title":"Hypertension."},{"issue":"3","key":"10.1016\/j.ejim.2023.06.008_bib0093","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCGEN.121.003554","article-title":"Blood pressure polygenic scores are associated with apparent treatment-resistant hypertension","volume":"15","author":"Breeyear","year":"2022","journal-title":"Circ Genom Precis Med"},{"issue":"13","key":"10.1016\/j.ejim.2023.06.008_bib0094","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1093\/eurheartj\/ehs455","article-title":"Genes for blood pressure: an opportunity to understand hypertension","volume":"34","author":"Ehret","year":"2013","journal-title":"Eur Heart J"},{"issue":"11","key":"10.1016\/j.ejim.2023.06.008_bib0095","first-page":"1345","article-title":"Gene therapy for hypertension","volume":"17","author":"Paulis","year":"2017","journal-title":"Expert Opin Biol Ther."},{"issue":"5","key":"10.1016\/j.ejim.2023.06.008_bib0096","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1001\/jama.285.5.545","article-title":"Gene and stem cell therapies","volume":"285","author":"Kaji","year":"2001","journal-title":"JAMA"},{"issue":"12","key":"10.1016\/j.ejim.2023.06.008_bib0097","doi-asserted-by":"crossref","first-page":"3281","DOI":"10.1161\/01.CIR.94.12.3281","article-title":"Direct intramuscular gene transfer of naked DNA encoding vascular endothelial growth factor augments collateral development and tissue perfusion","volume":"94","author":"Tsurumi","year":"1996","journal-title":"Circulation"},{"issue":"17","key":"10.1016\/j.ejim.2023.06.008_bib0098","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1161\/01.CIR.103.17.2138","article-title":"Randomized, single-blind, placebo-controlled pilot study of catheter-based myocardial gene transfer for therapeutic angiogenesis using left ventricular electromechanical mapping in patients with chronic myocardial ischemia","volume":"103","author":"Vale","year":"2001","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.ejim.2023.06.008_bib0099","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/S0002-9149(03)00661-1","article-title":"One-year follow-up of direct myocardial gene transfer of vascular endothelial growth factor-2 using naked plasmid deoxyribonucleic acid by way of thoracotomy in no-option patients","volume":"92","author":"Fortuin","year":"2003","journal-title":"Am J Cardiol"},{"issue":"3","key":"10.1016\/j.ejim.2023.06.008_bib0100","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s003950170053","article-title":"In vivo myocardial gene transfer: optimization, evaluation and direct comparison of gene transfer vectors","volume":"96","author":"Wright","year":"2001","journal-title":"Basic Res Cardiol"},{"issue":"14","key":"10.1016\/j.ejim.2023.06.008_bib0101","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1089\/hum.1997.8.14-1645","article-title":"Gene transfer into the carotid artery using an adventitial collar: comparison of the effectiveness of the plasmid-liposome complexes, retroviruses, pseudotyped retroviruses, and adenoviruses","volume":"8","author":"Laitinen","year":"1997","journal-title":"Hum Gene Ther"},{"issue":"4","key":"10.1016\/j.ejim.2023.06.008_bib0102","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.ymthe.2004.01.015","article-title":"Long-term lowering of plasma cholesterol levels in LDL-receptor-deficient WHHL rabbits by gene therapy","volume":"9","author":"Kankkonen","year":"2004","journal-title":"Mol Ther"},{"issue":"17","key":"10.1016\/j.ejim.2023.06.008_bib0103","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1038\/sj.gt.3301269","article-title":"Baculovirus-mediated periadventitial gene transfer to rabbit carotid artery","volume":"7","author":"Airenne","year":"2000","journal-title":"Gene Ther"},{"issue":"7","key":"10.1016\/j.ejim.2023.06.008_bib0104","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1038\/sj.mt.6300175","article-title":"Current status of cardiovascular gene therapy","volume":"15","author":"Rissanen","year":"2007","journal-title":"Mol Ther"},{"issue":"1","key":"10.1016\/j.ejim.2023.06.008_bib0105","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1006\/mthe.2002.0638","article-title":"Increased vascularity detected by digital subtraction angiography after VEGF gene transfer to human lower limb artery: a randomized, placebo-controlled, double-blinded phase II study","volume":"6","author":"Makinen","year":"2002","journal-title":"Mol Ther"},{"issue":"21","key":"10.1016\/j.ejim.2023.06.008_bib0106","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1161\/01.CIR.0000070540.80780.92","volume":"107","author":"Hedman","year":"2003","journal-title":"Circulation"},{"issue":"1-2","key":"10.1016\/j.ejim.2023.06.008_bib0107","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ymgme.2003.08.016","article-title":"Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer","volume":"80","author":"Raper","year":"2003","journal-title":"Mol Genet Metab"},{"issue":"10","key":"10.1016\/j.ejim.2023.06.008_bib0108","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1089\/hum.1998.9.10-1481","article-title":"Adenovirus-mediated gene transfer to lower limb artery of patients with chronic critical leg ischemia","volume":"9","author":"Laitinen","year":"1998","journal-title":"Hum Gene Ther"},{"issue":"4","key":"10.1016\/j.ejim.2023.06.008_bib0109","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1161\/HYPERTENSIONAHA.114.03188","article-title":"Increased expression of angiotensin II type 2 receptors in the solitary-vagal complex blunts renovascular hypertension","volume":"64","author":"Blanch","year":"2014","journal-title":"Hypertension"},{"issue":"20","key":"10.1016\/j.ejim.2023.06.008_bib0110","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1038\/sj.gt.3302330","article-title":"Circadian renal rhythms influenced by implanted encapsulated hANP-producing cells in Goldblatt hypertensive rats","volume":"11","author":"Chen","year":"2004","journal-title":"Gene Ther"},{"issue":"7","key":"10.1016\/j.ejim.2023.06.008_bib0111","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1002\/jgm.563","article-title":"Encapsulated transgene cells attenuate hypertension, cardiac hypertrophy and enhance renal function in Goldblatt hypertensive rats","volume":"6","author":"Chen","year":"2004","journal-title":"J Gene Med"},{"issue":"4","key":"10.1016\/j.ejim.2023.06.008_bib0112","doi-asserted-by":"crossref","first-page":"311","DOI":"10.18632\/aging.100655","article-title":"Cardiac BNP gene delivery prolongs survival in aged spontaneously hypertensive rats with overt hypertensive heart disease","volume":"6","author":"Tonne","year":"2014","journal-title":"Aging"},{"issue":"4","key":"10.1016\/j.ejim.2023.06.008_bib0113","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1172\/JCI117847","article-title":"Direct gene delivery of human tissue kallikrein reduces blood pressure in spontaneously hypertensive rats","volume":"95","author":"Wang","year":"1995","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ejim.2023.06.008_bib0114","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1161\/01.HYP.25.4.715","article-title":"Muscle delivery of human kallikrein gene reduces blood pressure in hypertensive rats","volume":"25","author":"Xiong","year":"1995","journal-title":"Hypertension"},{"issue":"7","key":"10.1016\/j.ejim.2023.06.008_bib0115","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1111\/j.1745-7254.2008.00815.x","article-title":"Recombinant adeno-associated virus-mediated human kallikrein gene therapy prevents high-salt diet-induced hypertension without effect on basal blood pressure","volume":"29","author":"Yan","year":"2008","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.ejim.2023.06.008_bib0116","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1161\/01.HYP.30.3.307","article-title":"Prolonged reduction of high blood pressure with human nitric oxide synthase gene delivery","volume":"30","author":"Lin","year":"1997","journal-title":"Hypertension"},{"issue":"2","key":"10.1016\/j.ejim.2023.06.008_bib0117","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.ymthe.2005.02.025","article-title":"Targeting endothelial cells with adenovirus expressing nitric oxide synthase prevents elevation of blood pressure in stroke-prone spontaneously hypertensive rats","volume":"12","author":"Miller","year":"2005","journal-title":"Mol Ther"},{"issue":"1","key":"10.1016\/j.ejim.2023.06.008_bib0118","doi-asserted-by":"crossref","first-page":"2","DOI":"10.3109\/08037051.2016.1167355","article-title":"Regulatory mechanisms in arterial hypertension: role of microRNA in pathophysiology and therapy","volume":"26","author":"Klimczak","year":"2017","journal-title":"Blood Press"},{"issue":"12","key":"10.1016\/j.ejim.2023.06.008_bib0119","doi-asserted-by":"crossref","DOI":"10.3390\/biom11121771","article-title":"MicroRNAs regulating renin-angiotensin-aldosterone system, sympathetic nervous system and left ventricular hypertrophy in systemic arterial hypertension","volume":"11","author":"Improta-Caria","year":"2021","journal-title":"biomolecules"},{"issue":"7209","key":"10.1016\/j.ejim.2023.06.008_bib0120","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/nature07242","article-title":"The impact of micrornas on protein output","volume":"455","author":"Baek","year":"2008","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.ejim.2023.06.008_bib0121","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19113608","article-title":"Exercise training-induced changes in micrornas: beneficial regulatory effects in hypertension, type 2 diabetes, and obesity","volume":"19","author":"Improta Caria","year":"2018","journal-title":"Int J Mol Sci"},{"issue":"2","key":"10.1016\/j.ejim.2023.06.008_bib0122","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0226053","article-title":"The association between microRNA-21 and hypertension-induced cardiac remodeling","volume":"15","author":"Watanabe","year":"2020","journal-title":"PLOS One"},{"issue":"2","key":"10.1016\/j.ejim.2023.06.008_bib0123","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1086\/519979","article-title":"Human microRNA-155 on chromosome 21 differentially interacts with its polymorphic target in the AGTR1 3\u2032 untranslated region: a mechanism for functional single-nucleotide polymorphisms related to phenotypes","volume":"81","author":"Sethupathy","year":"2007","journal-title":"Am J Hum Genet"},{"issue":"2","key":"10.1016\/j.ejim.2023.06.008_bib0124","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/ajh.2010.211","article-title":"Interplay between miR-155, AT1R A1166C polymorphism, and AT1R expression in young untreated hypertensives","volume":"24","author":"Ceolotto","year":"2011","journal-title":"Am J Hypertens"},{"issue":"12","key":"10.1016\/j.ejim.2023.06.008_bib0125","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1016\/j.clinbiochem.2013.05.052","article-title":"Urinary exosome miRNome analysis and its applications to salt sensitivity of blood pressure","volume":"46","author":"Gildea","year":"2013","journal-title":"Clin Biochem"},{"issue":"17","key":"10.1016\/j.ejim.2023.06.008_bib0126","doi-asserted-by":"crossref","first-page":"e6417","DOI":"10.1097\/MD.0000000000006417","article-title":"micro-RNA screening and prediction model construction for diagnosis of salt-sensitive essential hypertension","volume":"96","author":"Qi","year":"2017","journal-title":"Medicine (Baltimore)"},{"issue":"4","key":"10.1016\/j.ejim.2023.06.008_bib0127","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19040927","article-title":"Non-coding RNA in the pathogenesis, progression and treatment of hypertension","volume":"19","author":"Leimena","year":"2018","journal-title":"Int J Mol Sci"},{"issue":"18","key":"10.1016\/j.ejim.2023.06.008_bib0128","doi-asserted-by":"crossref","first-page":"3624","DOI":"10.1093\/hmg\/ddt213","article-title":"MicroRNA-22 and promoter motif polymorphisms at the Chga locus in genetic hypertension: functional and therapeutic implications for gene expression and the pathogenesis of hypertension","volume":"22","author":"Friese","year":"2013","journal-title":"Hum Mol Genet"},{"issue":"12","key":"10.1016\/j.ejim.2023.06.008_bib0129","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.tibtech.2006.10.003","article-title":"The potential of oligonucleotides for therapeutic applications","volume":"24","author":"Fichou","year":"2006","journal-title":"Trends Biotechnol"},{"issue":"1","key":"10.1016\/j.ejim.2023.06.008_bib0130","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s11373-006-9128-0","article-title":"Beta-1 adrenergic receptor antisense-oligodeoxynucleotides ameliorates left ventricular remodeling in 2-Kidney, 1-Clip rats","volume":"14","author":"Liang","year":"2007","journal-title":"J Biomed Sci"},{"issue":"2","key":"10.1016\/j.ejim.2023.06.008_bib0131","doi-asserted-by":"crossref","first-page":"703","DOI":"10.3892\/mmr.2016.6038","article-title":"Downregulation of the beta1 adrenergic receptor in the myocardium results in insensitivity to metoprolol and reduces blood pressure in spontaneously hypertensive rats","volume":"15","author":"Huang","year":"2017","journal-title":"Mol Med Rep"},{"issue":"6","key":"10.1016\/j.ejim.2023.06.008_bib0132","first-page":"H2392","article-title":"Intravenous angiotensinogen antisense in AAV-based vector decreases hypertension","volume":"277","author":"Tang","year":"1999","journal-title":"Am J Physiol"},{"issue":"4","key":"10.1016\/j.ejim.2023.06.008_bib0133","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1124\/pr.118.017129","article-title":"Novel therapeutic approaches targeting the renin-angiotensin system and associated peptides in hypertension and heart failure","volume":"71","author":"Arendse","year":"2019","journal-title":"Pharmacol Rev"},{"issue":"3","key":"10.1016\/j.ejim.2023.06.008_bib0134","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1161\/HYPERTENSIONAHA.117.09755","article-title":"Blood pressure lowering and safety improvements with liver angiotensinogen inhibition in models of hypertension and kidney injury","volume":"70","author":"Mullick","year":"2017","journal-title":"Hypertension."},{"issue":"5","key":"10.1016\/j.ejim.2023.06.008_bib0135","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1161\/CIRCRESAHA.117.312422","article-title":"(Pro)renin receptor inhibition reprograms hepatic lipid metabolism and protects mice from diet-induced obesity and hepatosteatosis","volume":"122","author":"Ren","year":"2018","journal-title":"Circ Res"},{"issue":"2","key":"10.1016\/j.ejim.2023.06.008_bib0136","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1161\/ATVBAHA.118.311817","article-title":"Angiotensinogen and megalin interactions contribute to atherosclerosis-brief report","volume":"39","author":"Ye","year":"2019","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"6","key":"10.1016\/j.ejim.2023.06.008_bib0137","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1161\/HYPERTENSIONAHA.111.190108","article-title":"Brain-targeted (pro)renin receptor knockdown attenuates angiotensin II-dependent hypertension","volume":"59","author":"Li","year":"2012","journal-title":"Hypertension"},{"issue":"7","key":"10.1016\/j.ejim.2023.06.008_bib0138","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1161\/01.RES.85.7.614","article-title":"Sustained inhibition of angiotensin I-converting enzyme (ACE) expression and long-term antihypertensive action by virally mediated delivery of ACE antisense cDNA","volume":"85","author":"Wang","year":"1999","journal-title":"Circ Res"},{"key":"10.1016\/j.ejim.2023.06.008_bib0139","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1161\/01.HYP.30.3.363","article-title":"Losartan versus gene therapy: chronic control of high blood pressure in spontaneously hypertensive rats","volume":"30","author":"Lu","year":"1997","journal-title":"Hypertension"},{"issue":"14","key":"10.1016\/j.ejim.2023.06.008_bib0140","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1038\/sj.gt.3302768","article-title":"AAV delivery of mineralocorticoid receptor shRNA prevents progression of cold-induced hypertension and attenuates renal damage","volume":"13","author":"Wang","year":"2006","journal-title":"Gene Ther"},{"issue":"16","key":"10.1016\/j.ejim.2023.06.008_bib0141","doi-asserted-by":"crossref","first-page":"3523","DOI":"10.1113\/jphysiol.2014.275560","article-title":"Knockdown of mineralocorticoid or angiotensin II type 1 receptor gene expression in the paraventricular nucleus prevents angiotensin II hypertension in rats","volume":"592","author":"Chen","year":"2014","journal-title":"J Physiol"},{"issue":"2","key":"10.1016\/j.ejim.2023.06.008_bib0142","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1089\/hum.2016.047","article-title":"AAV delivery of endothelin-1 shRNA attenuates cold-induced hypertension","volume":"28","author":"Chen","year":"2017","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.ejim.2023.06.008_bib0143","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.122.027694","article-title":"Small interfering RNA therapeutics in hypertension: a viewpoint on vasopressor and vasopressor-sparing strategies for counteracting blood pressure lowering by angiotensinogen-targeting small interfering RNA","author":"Ranasinghe","year":"2022","journal-title":"J Am Heart Assoc"},{"issue":"Suppl_3","key":"10.1016\/j.ejim.2023.06.008_bib0144","doi-asserted-by":"crossref","DOI":"10.1161\/circ.142.suppl_3.14387","article-title":"Abstract 14387: dose-related reductions in blood pressure with a RNA interference (RNAi) therapeutic targeting angiotensinogen in hypertensive patients: interim results from a first-in-human phase 1 study of ALN-AGT01","volume":"142","author":"Huang","year":"2020","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.ejim.2023.06.008_bib0145","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.jacbts.2021.04.004","article-title":"Antisense inhibition of angiotensinogen with IONIS-AGT-LRx: results of phase 1 and Phase 2 Studies","volume":"6","author":"Morgan","year":"2021","journal-title":"JACC Basic Transl Sci"},{"issue":"11","key":"10.1016\/j.ejim.2023.06.008_bib0146","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1038\/s41440-019-0294-7","article-title":"Circular RNAs in hypertension: challenges and clinical promise","volume":"42","author":"Zaiou","year":"2019","journal-title":"Hypertens Res"},{"issue":"5","key":"10.1016\/j.ejim.2023.06.008_bib0147","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1161\/HYPERTENSIONAHA.121.14519","article-title":"Circadian rhythm, clock genes, and hypertension: recent advances in hypertension","volume":"78","author":"Costello","year":"2021","journal-title":"Hypertension"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620523002017?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620523002017?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T09:40:40Z","timestamp":1760607640000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620523002017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":147,"alternative-id":["S0953620523002017"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2023.06.008","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Future treatments in hypertension: Can we meet the unmet needs of patients?","name":"articletitle","label":"Article Title"},{"value":"European Journal of Internal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2023.06.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}